Read more about the article Codere Online Luxembourg, S.A. Files Annual 20-F Report, Regaining Nasdaq Compliance
Codere Online Luxembourg, S.A. Files Annual 20-F Report, Regaining Nasdaq Compliance

Codere Online Luxembourg, S.A. Files Annual 20-F Report, Regaining Nasdaq Compliance

Codere Online Luxembourg filed its 2024 annual report, regaining compliance with Nasdaq rules, pending final confirmation.Quiver AI SummaryCodere Online Luxembourg, S.A., a prominent online gaming operator in Spain and Latin…

Continue ReadingCodere Online Luxembourg, S.A. Files Annual 20-F Report, Regaining Nasdaq Compliance
Read more about the article Hyperscale Data, Inc. Sells Minority Stake in Pharmaceutical Company for $4.65 Million, Focuses on Michigan Data Center Development
Hyperscale Data, Inc. Sells Minority Stake in Pharmaceutical Company for $4.65 Million, Focuses on Michigan Data Center Development

Hyperscale Data, Inc. Sells Minority Stake in Pharmaceutical Company for $4.65 Million, Focuses on Michigan Data Center Development

Hyperscale Data sells minority interest in a pharmaceutical company for $4.65 million, focusing on data center expansion in Michigan.Quiver AI SummaryHyperscale Data, Inc. announced the sale of its minority equity…

Continue ReadingHyperscale Data, Inc. Sells Minority Stake in Pharmaceutical Company for $4.65 Million, Focuses on Michigan Data Center Development
Read more about the article Vera Therapeutics Reports Positive Results from ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy, Meeting Primary Endpoint
Vera Therapeutics Reports Positive Results from ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy, Meeting Primary Endpoint

Vera Therapeutics Reports Positive Results from ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy, Meeting Primary Endpoint

Atacicept met its primary endpoint in the ORIGIN Phase 3 trial, significantly reducing proteinuria in IgAN patients.Quiver AI SummaryVera Therapeutics, Inc. announced that its ORIGIN Phase 3 trial for atacicept,…

Continue ReadingVera Therapeutics Reports Positive Results from ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy, Meeting Primary Endpoint
Read more about the article Liquidia Corporation Announces Commercial Launch of YUTREPIA for Treatment of Pulmonary Arterial Hypertension Following FDA Approval and Legal Ruling
Liquidia Corporation Announces Commercial Launch of YUTREPIA for Treatment of Pulmonary Arterial Hypertension Following FDA Approval and Legal Ruling

Liquidia Corporation Announces Commercial Launch of YUTREPIA for Treatment of Pulmonary Arterial Hypertension Following FDA Approval and Legal Ruling

Liquidia announces FDA approval and commercial launch of YUTREPIA for treating pulmonary arterial hypertension and PH-ILD.Quiver AI SummaryLiquidia Corporation has announced that its inhalation powder YUTREPIA™ (treprostinil) is now available…

Continue ReadingLiquidia Corporation Announces Commercial Launch of YUTREPIA for Treatment of Pulmonary Arterial Hypertension Following FDA Approval and Legal Ruling
Read more about the article Piedmont Office Realty Trust Announces Participation in Nareit REITWeek and Increases 2025 Leasing Guidance
Piedmont Office Realty Trust Announces Participation in Nareit REITWeek and Increases 2025 Leasing Guidance

Piedmont Office Realty Trust Announces Participation in Nareit REITWeek and Increases 2025 Leasing Guidance

Piedmont Office Realty Trust announces significant second quarter leasing success and participation in Nareit REITWeek Investor Conference in NYC.Quiver AI SummaryPiedmont Office Realty Trust, Inc. announced its participation in the…

Continue ReadingPiedmont Office Realty Trust Announces Participation in Nareit REITWeek and Increases 2025 Leasing Guidance

End of content

No more pages to load

Newer Posts
Older Posts